BUSPIRONE HYDROCHLORIDE EFFECTS ON HOSPITALIZATIONS FREQUENCY IN PATIENTS WITH CHRONIC HEART FAILURE AND MIXED ANXIETY-DEPRESSIVE DISORDER
https://doi.org/10.20514/2226-6704-2017-7-2-115-120
Abstract
Aim. Assessing the impact of buspirone hydrochloride on hospitalizations frequency in patients with chronic heart failure (CHF) and mixed anxietydepressive disorder (MADD).
Materials and methods. The study involved 49 patients with heart failure of ischemic etiology and MADD. Patients in Group 1 (n = 25) received buspirone hydrochloride (in the starting dose of 15 mg/day with a gradual (within 2 weeks) increasing to the effective (30 mg/day)) in addition to standard CHF therapy and coronary heart disease (CHD). Patients in group 2 (n = 24) received standard therapy of CHF and CHD. After 6 months, we evaluated hospitalizations frequency and duration in patients from both groups.
Results. The risk of hospitalization for heart failure decompensation was significantly lower in patients from group 1 compared with patients from group 2 (HR 0.333, 95% CI 1,12-8,05, p = 0.035).
Conclusions. Buspirone hydrochloride admission in addition to standard therapy is associated with reduced risk of hospitalization for decompensation of chronic heart failure in patients with MADD.
References
1. Арутюнов Г.П. Национальный проект ОРАКУЛ-РФ. Отчет о завершении исследования. Москва. VIII Национальный конгресс терапевтов 20.11.2013. Arutyunov G.P. National Project ORACLE-RF. Completion of the study report. Moscow. VIII National Congress of Therapists 20.11.2013 [In Russian].
2. Арутюнов Г.П. Повторные госпитализации больных с синдромом острой декомпенсации ХСН. Особенности, прогностическая значимость, новые подходы к снижению риска их возникновения. Русский медицинский журнал: Кардиология. Эндокринология. 2013; 12: 612-616. Arutyunov G.P. Re-hospitalization of patients with syndrome of acute decompensated heart failure. Features, predictive value, new approaches to reduce the risk of their occurrence. Russian Medical Journal: Cardiology. Endocrinology. 2013; 12: 612-616 [In Russian].
3. Ватутин Н.Т., Христиченко М.А., Кетинг Е.В. Эффективность и безопасность буспирона гидрохлорида у пациентов с тревожнодепрессивными расстройствами и хронической сердечной недостаточностью ишемического генеза. Архів клінічної та експериментальної медицини. 2014; 23(1): 28-31. Vatutin N.T., Khristichenko M.A., Keting E.V. Efficacy and safety of buspirone hydrochloride in patients with anxiety and depressive disorders and chronic heart failure of ischemic origin. Archive of clinical and experimental medicine. 2014; 23 (1): 28-31 [In Russian].
4. Маляров С.А. Взаимозависимость кардиоваскулярной патологии и аффективных нарушений. Украинский медичний часопис. 2012; 6: 42-44. Malyarov S.A. The interdependence of cardiovascular disease and affective disorders. Ukrainian medical chasopys. 2012; 6: 42-44 [In Russian].
5. Ресина И.А. Выявление состояний депрессии и тревоги, качество жизни у больных с хронической сердечной недостаточностью. Актуальные вопросы военной и практической медицины. Сб. трудов II научно-практической конференции врачей Приволжско-Уральского военного округа. Оренбург. 2001. Resina I.A. Identifying of depression and anxiety, quality of life in patients with chronic heart failure. Actual questions of military and practical medicine. Collected papers of II scientific-practical medical conference of the Volga-Ural Military District. Orenburg. 2001 [In Russian].
6. Янковская В.Л. Депрессия и хроническая сердечная недостаточность. Молодой ученый. 2014; 17: 223-227. Yankovskaya V.L. Depression and chronic heart failure. Young scientist. 2014; 17: 223-227 [In Russian].
7. Carels R.A. The association between disease severity, functional status, depression and daily quality of life in congestive heart failure patients. R.A. Carels. Qual Life Res. 2004; 13(1): 63-72.
8. Chung M.L. Antidepressants do not improve event-free survival in patients with heart failure when depressive symptoms remain. M.L. Chung, R.L. Dekker, T.A. Lennie et al. Heart Lung. 2013; 42(2): 85-91.
9. Diez-Quevedo C. Depression, antidepressants, and long-term mortality in heart failure. C. Diez-Quevedo, J. Lupón, B. González. Int J Cardiol. 2013; 167(4); 1217-1225.
10. Holzapfel N. Self-care and depression in patients with chronic heart failure N. Holzapfel, B. Löwe, B.Wild et al. Heart Lung. 2009; 38(5): 392-397.
11. Jiang W, Alexander J, Christopher E et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch. Intern. Med. 2001; 161 (15): 1849–1856.
12. Sullivan M.D. Depression and health status in elderly patients with heart failure: a 6month prospective study in primary care. M.D. Sullivan, K. Newton, J. Hecht et al. Am. J. Geriatr. Cardiol. 2004; 13(5): 252-260.
13. Suzuki T. Impact of clustered depression and anxiety on mortality and rehospitalization in patients with heart failure. T. Suzuki, T. Shiga, K. Kuwahara. J. Cardiol. 2014; 64(6): 456-462.
14. Tsuyuki R.T. Acute precipitants of congestive heart failure exacerbations. R.T. Tsuyuki, R.S. McKelvie, J.M. Arnold et al. Arch. Intern. Med. 2001; 161(19): 2337-2342.
Review
For citations:
Khristichenko M.A. BUSPIRONE HYDROCHLORIDE EFFECTS ON HOSPITALIZATIONS FREQUENCY IN PATIENTS WITH CHRONIC HEART FAILURE AND MIXED ANXIETY-DEPRESSIVE DISORDER. The Russian Archives of Internal Medicine. 2017;7(2):115-120. (In Russ.) https://doi.org/10.20514/2226-6704-2017-7-2-115-120
Views:
19613
Email this article 